Novus Therapeutics (NVUS) Misses Q3 EPS by $3.25

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. UPS
9. KIDS
10. LSTR

Go back to Novus Therapeutics (NVUS) Misses Q3 EPS by $3.25

Novus Therapeutics Reports Third Quarter 2020 Financial Results

November 16, 2020 4:00 PM EST

Company to host conference call and webcast at 4:30pm ET today

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today reported its financial results for the quarter ended September 30, 2020, and operational highlights.

Recent Business Highlights

Completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical stage biotechnology company developing a next generation... More